About Us
- Contact Us
Our Technology
Our Science
- Pipeline
- Advantages of Gylden’s Candidates
News and Events
Menu Menu

You are here: Home1 / Conferences2 / A novel immunoproteomic approach to MHC class I-restricted peptide discovery...

A novel immunoproteomic approach to MHC class I-restricted peptide discovery for influenza CD8+ T cell adaptive vaccine development

13th February 2025

Share this entry

Share on Facebook
Share on Twitter
Share on Pinterest
Share on LinkedIn
Share on Tumblr
Share on Vk
Share on Reddit
Share by Mail

/wp-content/uploads/2024/10/CompanyName-300x300.png 0 0 gatekeeper /wp-content/uploads/2024/10/CompanyName-300x300.png gatekeeper2025-02-13 13:41:522025-02-17 08:35:11A novel immunoproteomic approach to MHC class I-restricted peptide discovery for influenza CD8+ T cell adaptive vaccine development

© Gylden Pharma

Website maintained by Digital Trading

Contact Us

Emergex’s Next Generation Vaccines: Naturally processed & presented MHC...Novel gene identification in the influenza virus infection model using multi-omics...